ZEROHour Newsletter: November 2021
Grow & Give is Stache-tastic!
Wow, our Grow & Give campaign is off to a great start. Thanks to our inspiring dudes, dudettes, and their teams who are doing a stache-tastic job, already raising over $121K so far this month!
Michael Dunne - $6,303.81
Warren Macey - $3,960.48
Paul Devlin - $2,708.82
Top Community Teams:
Hops & Handlebars - $3,152.10
Shaker Road BROvember - $1,442.13
Jimmy Charles Warriors - $1,420.00
First Responder Teams:
Marysville PD/FD - $6,481.64
Murrieta Police Department - $5,364.90
Parsippany PBA Local #131 - $4,650.00
Baird - NovemBeard 2021 - $12,854.51
Pfizer - $5,283.98
BSC Marlborough - $4,550.94
Wanna get in on the fun? There's still plenty of time to beard up, speak out, and do good.
ZERO's Prostate Cancer Summit Shifts to Virtual Format
ZERO's Prostate Cancer Summit, the most impactful week in the movement to end prostate cancer, is set for March 4-8, 2022. Since our last outreach, there has been a change in the nature of the event. Due to concerns for safety in the light of COVID-19, the decision has been made by ZERO, the Chair of ZERO's Medical Advisory Board, and Board of Directors to make the Summit 100% virtual in 2022.
Despite the change to a virtual event, we are planning the same informative and interactive educational sessions, networking opportunities, award ceremonies, advocacy initiatives, and more. The Summit kicks off Friday evening with our Bold for Blue Awards Ceremony to celebrate our amazing and inspiring community. Education sessions will take place Saturday and Sunday.
On Monday various support groups will meet to offer fellowship, support, and resources. The Summit concludes Tuesday with an Advocacy Day for advocates to virtually meet and share their stories with their elected officials on the importance of increasing funding for the Prostate Cancer Research Program to $120M. Many more details will be headed your way in the upcoming months. We can't wait to connect with you at the Summit!
Veteran's Prostate Cancer Treatment and Research Act
Clinical pathways are a vital tool in the fight against prostate cancer. Clinical pathways improve quality, treatment, and access for patients with a standardized system of care. Currently, no such national clinical pathway exists for prostate cancer within the Veterans Health Administration (VHA). The Veteran's Prostate Cancer Treatment and Research Act is a critical piece of legislation in the House and Senate that will help to ensure that Veterans will have equal access to the best possible care by establishing a national clinical pathway for prostate cancer within the VHA.
Sign a petition in support of the bill and signal your Members of Congress that this legislation is vital for the health and well-being of our Veterans.
Save The Date For #GivingTuesday
Tuesday, November 30th is Giving Tuesday and ZERO invites you to be part of this special day of generosity. As part of our coverage, you'll meet prostate cancer patients and survivors who are going above and beyond to raise awareness. You'll also meet caregivers and ZERO Champions who are banding together to zero out this disease.
Because of the pandemic, prostate cancer patients are still experiencing heartbreaking interruptions in treatments and delays in annual screenings, and they face numerous other obstacles as the pandemic continues. Patients and their families need you urgently and Giving Tuesday is your opportunity to make a difference. Join us at zerocancer.org and on all of ZERO's social media platforms for our special Giving Tuesday coverage.
November is National Family Caregiver Month
Anyone can be a caregiver for a man battling prostate cancer, and sometimes it's easy for the men and women caring for cancer patients to feel stressed and lonely. We all know it's important for caregivers to have someone to talk to, to lean on, and just share. Our Caregiver Connector Mentor Program is there for them and can connect prostate cancer caregivers with ongoing one-on-one support from a Caregiver Mentor. ZERO's Caregiver Mentors have cared for their brothers, fathers, husbands, sons, partners, grandfathers, friends, and neighbors and are trained to offer support at a critical time. If you or someone you know is in need of this support, please point them to ZERO. And while you're at it, check out our 2021 Caregiver Town Hall on Facebook.
Meet Our New ZERO Team Members
ZERO's team is now four members stronger as Us TOO has officially merged with ZERO. We're excited to introduce you to our new ZERO family members.
Terri Likowski joins ZERO as Director of Us TOO Support Groups and leads 200+ prostate cancer support groups across the U.S.
Joining ZERO as our new Midwest Chapter Manager is Tracy Cameron. You may recognize her not only from her days at Us TOO, but also as a former Race Director for ZERO's Run/Walk in Joliet, IL.
The MarComm team is gaining a Director of Program Marketing, Tim Mix, who was the one-man band behind all of Us TOO's marketing and communications initiatives.
James Hutson joins as Director of Development and he will serve and partner with donors as well as develop new grant opportunities.
Head over to our website to learn more about each of our new rock star team members.
Introducing P-PSMA-101: CAR-T for prostate cancer
The P-PSMA-101-001 study is a Phase 1 clinical trial now enrolling patients at multiple locations in the United States. Conducted by Poseida Therapeutics, this study is testing P-PSMA-101, a new immunotherapy called a CAR-T.
P-PSMA-101 is made from your own white blood cells that have been genetically modified in a lab to recognize a protein called PSMA. PSMA is commonly located on the surface of prostate cancer cells and P-PSMA-101 is designed to kill the cancer cell. P-PSMA 101 is given via an intravenous infusion and you may be eligible to receive one or more infusions during the study.
The purpose of this study is to determine if P-PSMA-101 is safe and will help treat patients with metastatic prostate cancer. You may be eligible for the study if you have progressing metastatic, castration resistant prostate cancer; and you have already been treated with a 2nd generation hormone therapy and a chemotherapy called a taxane.
For more information about the P-PSMA-101-001 study including hospitals enrolling patients visit the study registry at: https://bit.ly/3mPobms or contact Poseida at (858) 779-3103 or email@example.com.
(This content is provided in partnership with Poseida Therapeutics.)
Hops & Handlebars Raising Money
Grow & Givers Ryan and Anna Pessah have been ZERO Champions for several years after Ryan lost his father to prostate cancer. They are Team Captains of the Hops & Handlebars Grow and Give team and have already raised more than $3,000 this year alone. Hops & Handlebars partners with businesses and organizations in Sacramento, California to host events, raise money and spread awareness about prostate cancer.
» Click here to join and donate
Help Us Understand Appetite Loss and Advanced Cancer
Many people with advanced cancer struggle with low appetite levels and the weight loss that comes with it. That's why we are researching a study drug—to understand its effect on appetite in people who are experiencing loss of appetite, unintentional weight loss, weakness, and fatigue caused by advanced cancer.
» Click here to find out more
(This content is provided in partnership with Pfizer.)
Successes of 2020
Our ZERO 2020 Annual Report features our impact that you helped make happen this past year. Together, we pivoted to address what was most important during the pandemic. "Thanks to the loyalty and generosity of our supporters, I am confident our efforts to help save the lives of men diagnosed with prostate cancer will continue to be a force for good in these dark times," said ZERO CEO/President Jamie Bearse.
» View the 2020 Annual Report
Do you have metastatic castrate-resistant prostate cancer? A trial investigating safety & efficacy of a new treatment may be an option for you.
» Learn More
(This content is provided in partnership with Taiho.)
Open Enrollment is Here
Over the upcoming weeks you have the opportunity to sign up for benefits or make changes to your healthcare coverage. Dates to note for coverage that starts on January 1, 2022: December 15 is the deadline to apply, renew, or change health insurance; Medicare's open enrollment deadline is December 7. If you are a prostate cancer patient and have questions about open enrollment or need assistance, connect with a ZERO360 Case Manager at (844) 244-1309.
» Open Enrollment
Genetic Factors in Prostate Cancer Treatment
There's a new study on the inherited genetic factors' impact on prostate cancer risk and treatment. The PROMISE study seeks to learn more about the roles genes can play in improving outcomes for prostate cancer patients.
» Learn More
(This content is provided in partnership with PROMISE study.)
Advanced Prostate Cancer Clinical Trial
Have you been diagnosed with advanced prostate cancer? If so, you should talk with your healthcare provider about whether or not a clinical trial is the right treatment option for you. Researchers for this Bristol Myers Squibb study are in need of candidates with advanced prostate cancer. You can find more details here:
(This content is provided in partnership with Bristol Myers Squibb.)
This edition of the ZEROHour Newsletter supported by: